You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Hydrocortisone - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for hydrocortisone and what is the scope of freedom to operate?

Hydrocortisone is the generic ingredient in seventy-six branded drugs marketed by Allergan Herbert, Crown Labs, Salix Pharms, Bayer Pharms, Monarch Pharms, Valeant Pharm Intl, Westwood Squibb, Pharm Assoc, C And M Pharma, Actavis Mid Atlantic, Alpharma Us Pharms, Altana, Ambix, Chartwell Molecular, Encube, Everylife, Fougera Pharms Inc, G And W Labs, Ingram Pharm, Ivax Pharms, Naska, Padagis Us, Perrigo New York, Pharmaderm, Pharmafair, Rising, Stiefel, Syosset, Taro, Teva, Topiderm, Usl Pharma, Whiteworth Town Plsn, Valeant Intl, Bausch, Chartwell, Ani Pharms, Teva Pharms, Healthpoint, Eton, Pharmacia And Upjohn, Baker Norton, Legacy Pharma, Solvay, Beta Dermac, Bluline, Heran, Fougera Pharms, Mericon, Dow Pharm, Pfizer Global, Cmp Pharma Inc, Dermik Labs, Torch, X Gen Pharms, Paddock Llc, Mission Pharma, Pfizer, Aurobindo Pharma Ltd, Barr, Elkins Sinn, Ferrante, Hikma Intl Pharms, Impax Labs, Impax Labs Inc, Inwood Labs, Nexgen Pharma Inc, Panray, Parke Davis, Purepac Pharm, Roxane, Sandoz, Strides Pharma, Watson Labs, Merck, Pfipharmecs, Mylan Speciality Lp, Able, Cenci, Imperium, Sebela Ireland Ltd, Bel Mar, Epic Pharma Llc, Fera Pharms, Colgate, Genus, Ferndale Labs, Glenmark Pharms Ltd, Taro Pharm Inds, Yamanouchi, Precision Dermat, Lupin Ltd, The J Molner, Abbott, Hospira, Abraxis Pharm, Baxter Hlthcare, Cipla, Intl Medication, Cosette, Encube Ethicals, Padagis Israel, Sun Pharm Inds Inc, Amring Pharms, Bausch And Lomb, Casper Pharma Llc, Schering, Actavis Labs Fl Inc, Forest Labs, Lederle, and Bioglan, and is included in two hundred and fifty-nine NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Hydrocortisone has fifty-six patent family members in twenty-five countries.

There are sixty-seven drug master file entries for hydrocortisone. Forty-one suppliers are listed for this compound.

Summary for hydrocortisone
Drug Prices for hydrocortisone

See drug prices for hydrocortisone

Drug Sales Revenue Trends for hydrocortisone

See drug sales revenues for hydrocortisone

Recent Clinical Trials for hydrocortisone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of North Carolina, Chapel HillPhase 4
Orion Corporation, Orion PharmaPhase 3
Merck Sharp & Dohme LLCPhase 3

See all hydrocortisone clinical trials

Pharmacology for hydrocortisone
Medical Subject Heading (MeSH) Categories for hydrocortisone

US Patents and Regulatory Information for hydrocortisone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alpharma Us Pharms HYDROCORTISONE hydrocortisone LOTION;TOPICAL 087315-001 Jun 7, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Eton ALKINDI SPRINKLE hydrocortisone GRANULE;ORAL 213876-002 Sep 29, 2020 RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bluline EPICORT hydrocortisone LOTION;TOPICAL 083219-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Sun Pharm Inds Inc WESTCORT hydrocortisone valerate CREAM;TOPICAL 017950-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Valeant Intl HYTONE hydrocortisone CREAM;TOPICAL 080472-004 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for hydrocortisone

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Takeda Pharmaceuticals International AG Ireland Branch Plenadren hydrocortisone EMEA/H/C/002185
Treatment of adrenal insufficiency in adults.
Authorised no no no 2011-11-03
Diurnal Europe B.V. Alkindi hydrocortisone EMEA/H/C/004416
Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old).
Authorised no no no 2018-02-09
Diurnal Europe B.V. Efmody hydrocortisone EMEA/H/C/005105
Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.
Authorised no no no 2021-05-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for hydrocortisone

Country Patent Number Title Estimated Expiration
Japan 2014533679 副腎機能障害の治療 ⤷  Subscribe
South Africa 201403462 TREATMENT OF ADRENAL INSUFFICIENCY ⤷  Subscribe
European Patent Office 2780003 TRAITEMENT DE L'INSUFFISANCE SURRÉNALE (TREATMENT OF ADRENAL INSUFFICIENCY) ⤷  Subscribe
United Kingdom 201407380 ⤷  Subscribe
Poland 2780003 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for hydrocortisone

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0809498 SPC/GB10/012 United Kingdom ⤷  Subscribe PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0809498 10C0038 France ⤷  Subscribe PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Hydrocortisone Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Hydrocortisone

Market Overview

The hydrocortisone market is experiencing robust growth, driven by several key factors. Here’s a comprehensive look at the market dynamics and financial trajectory of this essential drug.

Market Size and Growth

The global hydrocortisone market is projected to grow significantly in the coming years. As of 2023, the market size was estimated at $1.43 billion, and it is expected to reach $1.52 billion in 2024, growing at a compound annual growth rate (CAGR) of 6.4%[1].

By 2028, the market is anticipated to expand to $1.96 billion, with a CAGR of 6.6% from 2023 to 2028. This growth is attributed to technological advancements, increased demand for over-the-counter (OTC) products, investments in research and development, growing disposable income, and expanded distribution channels[1].

Segmentation

The hydrocortisone market is segmented based on several criteria:

By Type

  • Creams
  • Injections
  • Tablets

Each of these segments contributes to the overall market growth, with creams being a significant portion due to their widespread use in treating skin disorders[1].

By Route of Administration

  • Parenteral
  • Oral
  • Topical

Topical applications, such as creams and ointments, are particularly popular due to their ease of use and effectiveness in treating dermatological conditions[1].

By Application

  • Adrenocortical Dysfunction
  • Adrenergic Syndrome
  • High Blood Calcium
  • Thyroiditis
  • Rheumatoid Arthritis
  • Dermatitis
  • Asthma and Chronic Obstructive Pulmonary Disease (COPD)
  • Other Applications

The diverse range of applications underscores the versatility and importance of hydrocortisone in various medical treatments[1].

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

The expansion of online pharmacies has significantly contributed to the market's growth, making hydrocortisone products more accessible to consumers[1].

Market Drivers

Several factors are driving the growth of the hydrocortisone market:

Rising Prevalence of Skin Disorders

The increasing incidence of skin conditions such as dermatitis, eczema, and other cutaneous disorders is a major driver. As the population ages and awareness about skin health increases, the demand for hydrocortisone products, especially creams and ointments, is on the rise[1][3].

Technological Advancements

Advancements in formulation and delivery systems, such as hydrocortisone-infused products and combination therapies, are enhancing the efficacy and appeal of hydrocortisone treatments. These innovations are attracting more consumers and healthcare providers to the market[1].

Increased Investment in Research and Development

Pharmaceutical companies are investing heavily in research and development to improve existing products and develop new ones. For instance, Eton Pharmaceuticals has successfully completed a pivotal bioequivalence study for its proprietary oral hydrocortisone formulation, ET-400, which is expected to be submitted for FDA approval in Q2 2024[2].

Growing Disposable Income

As global disposable income increases, more people are able to afford healthcare products, including hydrocortisone. This economic factor is particularly significant in emerging markets where access to healthcare is improving[1].

Financial Performance

Revenue Growth

Companies involved in the hydrocortisone market are experiencing significant revenue growth. For example, Eton Pharmaceuticals reported a 109% year-over-year increase in product sales and royalty revenue in Q4 2023, reaching $7.3 million. This marks the twelfth consecutive quarter of sequential product sales growth for the company[2].

Regional Market Performance

The global hydrocortisone cream market, a subset of the broader hydrocortisone market, is also showing strong regional performance. North America holds a major share, with a market size of $540.88 million in 2024 and a CAGR of 4.7% from 2024 to 2031. Europe and Asia Pacific also have significant market shares, with CAGRs of 5.0% and 8.5%, respectively, over the same period[3].

Market Trends

Natural Ingredient Focus

There is a growing trend towards natural and organic ingredients in healthcare products. Hydrocortisone, being a natural corticosteroid, aligns well with this trend, making it more appealing to consumers seeking natural remedies[1].

Combination Therapies

Combination therapies that include hydrocortisone along with other medications are gaining popularity. These therapies offer enhanced treatment outcomes and are driving the market forward[1].

Personalized Treatments

The move towards personalized medicine is also influencing the hydrocortisone market. Tailored treatments that use hydrocortisone in specific formulations are becoming more common, catering to individual patient needs[1].

Sustainability Emphasis

Sustainability is another key trend, with companies focusing on environmentally friendly packaging and production processes. This emphasis on sustainability is expected to continue driving the market as consumers become more environmentally conscious[1].

Cost Analysis and Economic Impact

Cost Benefits

Adjunctive hydrocortisone therapy has been shown to have significant cost benefits, particularly in the treatment of septic shock. A study estimated that this therapy could result in a monetized benefit of up to $25,539 per patient by reducing ICU stays, vasopressor-free days, and ventilation-free days[4].

Total Estimated Annual Impact

The total estimated annual impact of adjunctive hydrocortisone therapy for septic shock was $2.3 billion in 2019 dollars, highlighting the economic significance of hydrocortisone in critical care settings[4].

Key Takeaways

  • The hydrocortisone market is growing at a CAGR of 6.6% from 2023 to 2028.
  • Key drivers include rising skin disorder prevalence, technological advancements, and increased investment in R&D.
  • The market is segmented by type, route of administration, application, and distribution channel.
  • Regional markets, especially North America, Europe, and Asia Pacific, are significant contributors to the global market.
  • Trends such as natural ingredient focus, combination therapies, personalized treatments, and sustainability emphasis are shaping the market.
  • Hydrocortisone therapy shows significant cost benefits, particularly in critical care settings.

FAQs

What is the projected market size of the hydrocortisone market by 2028?

The hydrocortisone market is expected to reach $1.96 billion by 2028, growing at a CAGR of 6.6% from 2023 to 2028[1].

What are the main drivers of the hydrocortisone market growth?

The main drivers include the rising prevalence of skin disorders, technological advancements, increased investment in R&D, growing disposable income, and expanded distribution channels[1].

Which regions hold significant market shares in the hydrocortisone cream market?

North America, Europe, and Asia Pacific hold significant market shares, with North America accounting for over 40% of the global revenue[3].

What are some of the key trends in the hydrocortisone market?

Key trends include a focus on natural ingredients, combination therapies, personalized treatments, hydrocortisone-infused products, and an emphasis on sustainability[1].

What is the estimated cost benefit of adjunctive hydrocortisone therapy for septic shock?

The estimated cost benefit of adjunctive hydrocortisone therapy for septic shock can be up to $25,539 per patient, driven by reductions in ICU stays, vasopressor-free days, and ventilation-free days[4].

Sources

  1. The Business Research Company, Global Hydrocortisone Market Report 2024.
  2. Eton Pharmaceuticals, Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results.
  3. Cognitive Market Research, Hydrocortisone Cream Market Report 2024 (Global Edition).
  4. PubMed, Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.